Gilead Sciences Inc.’s Trodelvy extended by 1.5 months, or 34 percent, the length of time women with advanced stages of a common type of breast cancer lived without their disease worsening, according to trial data presented on Saturday.
The Phase III study compared Trodelvy to chemotherapy in 543 patients with hormone-sensitive tumors that test negative for a receptor called HER2 and who had stopped responding to at least two earlier lines of therapy.
